IL2 and systemic lupus erythematosus: Low-dose IL-2 therapy also preferentially augmented the proliferation of Foxp3+CD127lo Treg resulting in a partial restoration of the homeostatic balance between Treg and Tcon, which is typically disturbed in SLE patients.